Combined erbB/VEGFR blockade has improved anticancer activity over single-pathway inhibition in ovarian cancer in vivo
Thahir Farzan(Mayo Clinic), Paul Haluska(Mayo Clinic in Arizona), Kimberly R. Kalli(Mayo Clinic), S. John Weroha(Mayo Clinic), Sean C. Harrington(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Xinwei Hou(Mayo Clinic)
Cited by 0
Related Papers
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
|The Lancet Oncology|2013|434
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
|JAMA Oncology|2017|409
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
|The Journal of Immunology|2011|250
Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19
|The Journal of Experimental Medicine|2021|232
The molecular origin and taxonomy of mucinous ovarian carcinoma
|Nature Communications|2019|191